14121 studies found for:    Canada
Show Display Options
Rank Status Study
1 Enrolling by invitation Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention:
2 Recruiting Observational Study of Golimumab Intravenous Infusion
Condition: Rheumatoid Arthritis
Intervention: Biological: Golimumab Intravenous
3 Recruiting A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Condition: Prostatic Neoplasms
Intervention: Other: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
4 Recruiting Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention:
5 Recruiting Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
Condition: Major Depressive Disorder
Intervention: Drug: vortioxetine
6 Recruiting Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
Condition: Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
7 Recruiting Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol;   Drug: tiotropium
8 Recruiting Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MEDI4736;   Drug: Placebo
9 Recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696
10 Recruiting A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Condition: Psoriasis
Interventions: Drug: Guselkumab 100 mg;   Drug: Placebo for guselkumab;   Drug: Adalimumab;   Drug: Placebo for adalimumab
11 Recruiting A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Condition: Psoriasis
Interventions: Drug: Ustekinumab;   Drug: Guselkumab;   Drug: Placebo for ustekinumab;   Drug: Placebo for guselkumab
12 Recruiting Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
Condition: Psoriasis
Interventions: Drug: Adalimumab;   Drug: Methotrexate
13 Recruiting A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: fluticasone furoate (FF);   Drug: vilanterol (VI);   Drug: umeclidinium bromide (UMEC)
14 Recruiting OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
Condition: Chonic Spontaneous Urticaria
Intervention: Drug: omalizumab
15 Recruiting A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
Condition: Asthma
Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid;   Drug: terbutaline 'as needed' + placebo budesonide bid;   Drug: budesonide bid + terbutaline 'as needed'
16 Recruiting Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Condition: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
17 Recruiting Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Condition: Hyperlipidemia
Interventions: Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
18 Recruiting Transfusion Requirements in Cardiac Surgery III
Condition: Disorder; Heart, Functional, Postoperative, Cardiac Surgery
Interventions: Other: Restrictive Transfusion Strategy;   Other: Liberal transfusion strategy
19 Recruiting A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Conditions: Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
Interventions: Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
20 Completed Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
Condition: Influenza
Intervention: Drug: favipiravir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years